First new antibiotic class in decades
A genuinely new way of killing bacteria that have learned to survive every antibiotic we have.
30%likely
Well sourced
Next check
Watching
Why it is different
The mispricing is commercial, not scientific. Everyone assumes antibiotics never make money, so the clinical result gets ignored entirely.
Why it matters
Drug-resistant infection is a slow-moving crisis and the pipeline has been close to empty for decades.
Next check · 24 Oct 2026
Does Roche present zosurabalpin results from infected patients at IDWeek in October 2026?
How we scored it ·
from how often this kind of thing happens
If right, how big4/5How overlooked4/5Upside vs downside2/5Source trust4/5Independent sources3/5
The exact wording we score
A novel-MOA gram-negative antibiotic from a set named today hits a positive pivotal by end-2030.